Efficiency of unani formulation in ringworm disease
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2022/03/041124
- Lead Sponsor
- ational Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
ï??Patients aged 18-60 years of either sex with a clinical diagnosis of Tinea corporis and/or Tinea cruris with <= 5% body surface area involvement
ï??Patients with Global assessment score of >= 5 with positive KOH mount
ï??Patients who will give consent and are able to do follow up
ï??Immuno-compromised patients
ï??Patients with extensive Dermatophytosis, other forms of tinea infections, superadded bacterial infection
ï??Patients with contact dermatitis, atopic dermatitis, psoriasis, other skin diseases
ï??Patients with a history of hypersensitivity to allylamine antifungals
ï??Patients who received topical antifungal within 1 week and systemic antifungals within 4 weeks prior to enrolment
ï??Patients with a known history or clinical evidence of bleeding disorders, severe systemic illness and uncontrolled diabetes mellitus
ï??Pregnant and lactating females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of achieved complete clearance among groups at the end of treatmentTimepoint: Baseline and after treatment
- Secondary Outcome Measures
Name Time Method a.Comparison of achieved clinical cure among groups at the end of treatment <br/ ><br>b.Comparison of achieved Mycological cure among groups at the end of treatment <br/ ><br>c.Comparison of relapse among groups at the end of treatment <br/ ><br>d.Improvement in DLQI <br/ ><br>Timepoint: before and After study